A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Boehringer Ingelheim
Hoffmann-La Roche
Jiangsu HengRui Medicine Co., Ltd.
Bristol-Myers Squibb
Taiho Oncology, Inc.
Merck Sharp & Dohme LLC
Boehringer Ingelheim
Gilead Sciences
Pfizer
AstraZeneca
Revolution Medicines, Inc.
AstraZeneca
Hoffmann-La Roche
Regeneron Pharmaceuticals
Inhibrx Biosciences, Inc
BeiGene
Merck Sharp & Dohme LLC
Mirati Therapeutics Inc.
Avistone Biotechnology Co., Ltd.
Bristol-Myers Squibb
Checkpoint Therapeutics, Inc.
EpicentRx, Inc.
Novartis
BeiGene
NantCell, Inc.
EpicentRx, Inc.
Incyte Corporation
Regeneron Pharmaceuticals
Eli Lilly and Company
R-Pharm
Bayer
Eli Lilly and Company
Eli Lilly and Company
Incyte Corporation
Critical Outcome Technologies Inc.
CanBas Co. Ltd.
Shenzhen Hornetcorn Bio-technology Company, LTD
Eli Lilly and Company
Jiangsu Simcere Pharmaceutical Co., Ltd.
Sanofi
Merck KGaA, Darmstadt, Germany
Amgen
Clovis Oncology, Inc.
Sanofi